Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Management of AML: FLT3 Inhibitors and BCL2 Inhibitors

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

February 1st 2021

Role of FLT3 Inhibitors in Chemo-Ineligible AML

February 1st 2021

Selinexor Approaches EU Approval for Refractory Multiple Myeloma

January 30th 2021

January 29, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for selinexor for use in combination with dexamethasone in the treatment of select adult patients with refractory multiple myeloma.

Dr. Jabbour on the Rationale to Evaluate KO-539 in Relapsed/Refractory AML

January 29th 2021

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.

Third and Subsequent Line Options for Multiple Myeloma

January 29th 2021

Updates in Relapsed/Refractory Myeloma

January 29th 2021

DLBCL: Treatment Considerations for Challenging Populations

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

January 29th 2021

RRMM: Incorporating INN Melphalan Flufenamide Into Clinical Practice

January 28th 2021

RRMM: INN Melphalan Flufenamide After Alkylator Therapy

January 28th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

January 28th 2021

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

January 28th 2021

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Role of Therapeutic Intervention in SMM

January 27th 2021

Overview of Smoldering Multiple Myeloma

January 27th 2021

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.